Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.
Journal Article (Journal Article)
Pulmonary arterial hypertension (PAH) has emerging therapeutic options including prostacyclin analogs. Inhaled therapy offers advantages compared with alternative routes of administration. We aimed to determine the safety and tolerability of inhaled treprostinil (iTRE) titrated to target maintenance dose higher than the labeled dose for PAH. Our study included 80 consecutive patients (69% female, 70% White) followed at the Duke University Medical Center prescribed iTRE at dose >9 breaths (54 μg). Etiology of pulmonary hypertension was most frequently PAH (51%) or secondary to lung disease (35%). Median follow-up was 20.3 months (interquartile range 14.2-33.2). Most patients (91%) had titrated iTRE dose to 12 breaths (72 μg) four times daily. Common side effects reported with drug initiation were cough (41%), headache (28%), and throat irritation (8%); most of the side effects improved at follow-up. Overall, 25% patients discontinued iTRE: 9 transitioned to parenteral therapy, 4 had untolerable side effects, 3 died, and 4 had other reasons. Overall, iTRE taken at a higher dose than approved for use in PAH was safe and well-tolerated in our cohort of pulmonary hypertension patients.
Full Text
Duke Authors
Cited Authors
- Parikh, KS; Rajagopal, S; Fortin, T; Tapson, VF; Poms, AD
Published Date
- April 2016
Published In
Volume / Issue
- 67 / 4
Start / End Page
- 322 - 325
PubMed ID
- 26828324
Pubmed Central ID
- PMC4824653
Electronic International Standard Serial Number (EISSN)
- 1533-4023
Digital Object Identifier (DOI)
- 10.1097/FJC.0000000000000357
Language
- eng
Conference Location
- United States